[CAS NO. 867-44-7] S-Methylisothioureasulfate
PRODUCTS SPECIFICATIONS [867-44-7]
DESCRIPTION [867-44-7]
Overview
| MDL | MFCD00013055 |
|---|---|
| Molecular Weight | 139.18 |
| Molecular Formula | C2H6N2S.1/2H2O4S |
| SMILES | NC(SC)=N.O=S(O)(O)=O.[1/2] |
1 Publications Citing Use of MCE
Summary
S-Methylisothiourea sulfate is a potent, selective and competitive inhibitor of inducible nitric oxide synthase (iNOS) . S-Methylisothiourea sulfate exerts beneficial effects in rodent models of septic shock [1] .
IC50 & Target
iNOS [1]
In Vitro
S-Methylisothiourea sulfate is a competitive inhibitor of iNOS activity at the L-arginine site
[1]
.
S-Methylisothiourea sulfate prevents the NO-mediated cytotoxic effect of LPS in cultured macrophages
[1]
.
S-Methylisothiourea sulfate (100 nM-100 μM) exhibits inhibitory effects on LPS (ug/mL)-induced nitrite production in J774.2 macrophages and rat aortic vascular smooth muscle cells
[1]
.
S-Methylisothiourea sulfate (up to 1 mM) does not inhibit the activity of xanthine oxidase, diaphorase, lactate dehydrogenase, monoamine oxidase, catalase, cytochrome P450, or superoxide dismutase
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
S-Methylisothiourea sulfate (0.01-3 mg/kg; i.v.) dose-dependently reverses the hypotension and the vascular hyporeactivity to vasoconstrictor agents caused by endotoxin LPS in anesthetized rats
[1]
.
S-Methylisothiourea sulfate (5 mg/kg; i.p.; given 2 hr after LPS; 10 mg/kg; i.p.) attenuates the rises in plasma alanine and aspartate aminotransferases, bilirubin, and creatinine and also prevents hypocalcaemia when measured 6 hr after administration of LPS
[1]
.
S-Methylisothiourea sulfate (1 mg/kg; i.p.) improves 24-hr survival of mice treated with a high dose of LPS (60 mg/kg; i.p.)
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Male Wistar rats (260-320 g) [1] |
| Dosage: | 0.01 mg/kg, 0.1 mg/kg, 1 mg/kg, 3 mg/kg |
| Administration: | Intravenous injection |
| Result: | Caused a prompt restoration of the blood pressure to pre-LPS levels at 3 mg/kg dose in LPS (10 mg/kg, i.v.)-treated rats; Inhibited iNOS activity measured in homogenates of lung. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H 2 O : 65 mg/mL ( 467.02 mM ; Need ultrasonic)
DMSO : < 1 mg/mL (insoluble or slightly soluble)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 7.1849 mL | 35.9247 mL | 71.8494 mL |
| 5 mM | 1.4370 mL | 7.1849 mL | 14.3699 mL |
| 10 mM | 0.7185 mL | 3.5925 mL | 7.1849 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 50 mg/mL (359.25 mM); Clear solution; Need ultrasonic
Synonyms